4D Pharma Shares Jump on Clinical Collaboration With Germany's Merck, Pfizer
February 08 2021 - 02:41AM
Dow Jones News
By Adria Calatayud
Shares in 4D pharma PLC rose Monday after the company said it
has entered into a clinical-trial collaboration and supply
agreement with Germany's Merck KGaA and Pfizer Inc. for an oncology
treatment.
Under the collaboration, the U.K. pharmaceutical company said it
will start a clinical trial this year to evaluate BAVENCIO, a
maintenance treatment for urothelial carcinoma co-developed by
Merck and Pfizer, in combination with 4D pharma's MRx0518, a
biotherapeutic product in development for the treatment of
cancer.
The trial will evaluate the combination of BAVENCIO and MRx0518
as a first-line maintenance therapy for patients with locally
advanced or metastatic urothelial carcinoma that hasn't progressed
with first-line platinum-containing chemotherapy, 4D pharma
said.
Urothelial carcinoma is a common type of bladder cancer.
Shares in 4D pharma at 0803 GMT were up 9.1% at 144 pence.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
February 08, 2021 03:26 ET (08:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Feb 2024 to Mar 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2023 to Mar 2024
Real-Time news about 4d Pharma Plc (London Stock Exchange): 0 recent articles
More 4d Pharma Plc News Articles